
Sign up to save your podcasts
Or


In this episode of the pharmaphorum podcast, web editor Nicole Raleigh welcomed Dr Hans Eriksson, chief medical officer at HMNC Brain Health, a precision psychiatry biopharma company, to discuss his work exploring current studies into the use of ketamine in mental health, HMNC Brain Health having last year announced topline results from a Phase 2 study looking at a take-at-home, oral ketamine option for Treatment Resistant Depression (or TRD).
By pharmaphorum5
33 ratings
In this episode of the pharmaphorum podcast, web editor Nicole Raleigh welcomed Dr Hans Eriksson, chief medical officer at HMNC Brain Health, a precision psychiatry biopharma company, to discuss his work exploring current studies into the use of ketamine in mental health, HMNC Brain Health having last year announced topline results from a Phase 2 study looking at a take-at-home, oral ketamine option for Treatment Resistant Depression (or TRD).

755 Listeners

113,527 Listeners

337 Listeners

35 Listeners

20,515 Listeners